DJS Law Group Urges Investors to Participate in Immutep Class Action Lawsuit

Immutep Limited Faces Class Action Lawsuit for Securities Violations

In a significant legal development, Immutep Limited, a publicly traded biopharmaceutical company, is facing a class action lawsuit due to alleged violations of securities laws. The lawsuit, spearheaded by the DJS Law Group, highlights concerns over misrepresentations regarding the efficacy of Immutep’s clinical trials, particularly the TACTI-004 trial of their lead drug, eftilagimod alfa (efti).

Overview of Allegations

According to documents filed in the lawsuit, Immutep purportedly made false and misleading statements to its investors about the progress of the TACTI-004 trial. During a significant declare on January 30, 2026, the company claimed that the trial was showing "strong operational progress." However, the complaint contends that behind the scenes, Immutep was aware that the trial was unlikely to meet its primary endpoints, which are crucial for demonstrating the drug's effectiveness.

Important Class Period and Deadlines

The class action lawsuit covers a defined period: March 24, 2025, to March 12, 2026. Investors who purchased shares of Immutep during this time frame are encouraged to reach out to DJS Law Group if they wish to participate. Importantly, being appointed as a lead plaintiff is not a prerequisite for recovering potential losses, offering an opportunity for affected investors to join the case without the complexities of formal legal leadership.

Why Contact DJS Law Group?

The DJS Law Group is renowned for its commitment to maximizing investor returns through strategic legal counsel and robust representation in securities litigation. Their extensive experience in securities class actions and corporate governance adds significant credibility to the pursuit of this case against Immutep. The group emphasizes that each litigation claim is a valuable asset, warranting meticulous attention and effective advocacy.

Call to Action for Shareholders

Shareholders who believe they experienced financial losses as a result of Immutep's actions are urged to contact DJS Law Group. The firm provides an avenue for investors to recover their losses incurred during the misleading announcements and operational assessments. In previous instances, similar lawsuits have led to substantial recoveries for investors affected by corporate misconduct. This case could likely follow suit, and therefore, prompt action is encouraged.

Conclusion

As the situation unfolds, investors should remain informed about their rights and the legal options available to them in light of these serious allegations against Immutep Limited. The allegations underline the importance of transparency and accountability when it comes to public companies, particularly those in the biopharmaceutical sector where patient lives and investor trust are at stake. For those impacted, DJS Law Group stands ready to assist in navigating this complex landscape of securities law.

For further information and to determine the next steps, affected investors can contact:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]